Showing results (1921-1930 of 9,628) with videos related to
Sort By:
Pageof 963
Leukemia|January 26, 2019
Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylationR Jitschin, M Böttcher, D Saul, et al.Leukemia|January 27, 2019
The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologiesTaylor Harding, Linda Baughn, Shaji Kumar, et al.Leukemia|February 1, 2019
Rethinking clinical trial endpoints in myelodysplastic syndromesMikkael A Sekeres, David P SteensmaLeukemia|February 1, 2019
New roles for B cell receptor associated kinases: when the B cell is not the targetPhuong-Hien Nguyen, Emanuel Niesen, Michael HallekLeukemia|October 1, 1988
Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutationM Buschle, J W Janssen, H Drexler, et al.Leukemia|February 8, 2019
Data mining for mutation-specific targets in acute myeloid leukemiaBrooks Benard, Andrew J Gentles, Thomas Köhnke, et al.Leukemia|September 29, 2020
Correction: Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017Geneviève I C G Ector, Otto Visser, Peter E Westerweel, et al.Leukemia|September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseMeletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.Leukemia|July 1, 1988
Coincidence of a myeloproliferative and a lymphoproliferative disorder--a random event?T Ringbaek, H SchultzLeukemia|September 16, 2020
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemiaRémi Letestu, Abdelmalek Dahmani, Marouane Boubaya, et al.Pageof 963